Aktuellt
SENASTE
Redeye provides an initial take on Optomed’s Q3 2023 report. Sales during the quarter amounted to EUR4.2m (EUR3.7m) compared to our sales estimate of EUR4.0m. Moreover, EBIT came in at EUR-0.6m (EUR-1.4m), and the cash position at the end of the period amounted to EUR9.6m. Overall, the report was better than we anticipated, especially as cash flow from operating activities was positive during the quarter. We will provide a more in-depth update shortly, where we expect to only make minor changes in our estimates.
LÄS MER
